GAITHERSBURG, Md. , Oct. 15, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual

Comprehensive analysis shows AdCOVID uniquely   stimulates three key immune compon ents: serum neutralizing antibody , T cell responses , and mucosal immunity in the respiratory tract Nasal m ucosal i mmunity   may be the c ritical factor in   driving sterilizing immunity and p reventing f urther s

GAITHERSBURG, Md. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October: H.C. Wainwright 4 th Annual NASH Investor Conference

GAITHERSBURG, Md. , Sept. 28, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Scot Roberts , Ph.D., Chief Scientific Officer of Altimmune, Inc. , presented an overview of the Company’s AdCOVID and T-COVID intranasal vaccine

Company anticipates first-in-human trials to start in Q4 2020 GAITHERSBURG, Md. , Sept. 01, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the successful completion of multiple dose toxicity and toxicokinetic studies of ALT-801, a

GAITHERSBURG, Md. , Aug. 26, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced a preclinical data presentation on ALT-801, its balanced and long-acting GLP-1/glucagon receptor dual agonist under development for NASH, at the Digital

Antigen-specific CD4+ and CD8+ T cell responses in the lung not previously shown with advanced COVID-19 vaccine candidates GAITHERSBURG, Md. , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced additional positive results

GAITHERSBURG, Md. , Aug. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2020 and provided a business update. “We are pleased with Altimmune’s progress during 2020

GAITHERSBURG, Md. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate.

GAITHERSBURG, Md. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the three and six months ended June 30, 2020 and its business outlook before the market open and host a